Related references
Note: Only part of the references are listed.Immunostimulatory AdCD40L gene therapy combined with low-dose cyclophosphamide in metastatic melanoma patients
Angelica Loskog et al.
BRITISH JOURNAL OF CANCER (2016)
VEGF suppresses T-lymphocyte infiltration in the tumor microenvironment through inhibition of NF-κB-induced endothelial activation
Hua Huang et al.
FASEB JOURNAL (2015)
Understanding the Mysterious M2 Macrophage through Activation Markers and Effector Mechanisms
Tamas Roszer
MEDIATORS OF INFLAMMATION (2015)
Induction of T-cell Immunity Overcomes Complete Resistance to PD-1 and CTLA-4 Blockade and Improves Survival in Pancreatic Carcinoma
Rafael Winograd et al.
CANCER IMMUNOLOGY RESEARCH (2015)
PD-1/PD-L1 Blockade Together With Vaccine Therapy Facilitates Effector T-Cell Infiltration Into Pancreatic Tumors
Kevin C. Soares et al.
JOURNAL OF IMMUNOTHERAPY (2014)
CD40L gene therapy tilts the myeloid cell profile and promotes infiltration of activated T lymphocytes
L. Liljenfeldt et al.
CANCER GENE THERAPY (2014)
Multifunctional CD40L: pro- and anti-neoplastic activity
Aleksandra Korniluk et al.
TUMOR BIOLOGY (2014)
Treatment Efficacy and Immune Stimulation by AdCD40L Gene Therapy of Spontaneous Canine Malignant Melanoma
Sara Westberg et al.
JOURNAL OF IMMUNOTHERAPY (2013)
Elevated serum soluble CD40 ligand in cancer patients may play an immunosuppressive role
Jianping Huang et al.
BLOOD (2012)
Oncolytic Immunotherapy of Advanced Solid Tumors with a CD40L-Expressing Replicating Adenovirus: Assessment of Safety and Immunologic Responses in Patients
Sari Pesonen et al.
CANCER RESEARCH (2012)
Safety and Activity of Anti-PD-L1 Antibody in Patients with Advanced Cancer
Julie R. Brahmer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
CD40/CD4OL interaction induces E-selectin dependent leukocyte adhesion to human endothelial cells and inhibits endothelial cell migration
Daniel Urban et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2011)
CD40 Agonists Alter Tumor Stroma and Show Efficacy Against Pancreatic Carcinoma in Mice and Humans
Gregory L. Beatty et al.
SCIENCE (2011)
Immune modulation with weekly dosing of an agonist CD40 antibody in a phase I study of patients with advanced solid tumors
Jens Rueter et al.
CANCER BIOLOGY & THERAPY (2010)
AdCD40L Immunogene Therapy for Bladder Carcinoma-The First Phase I/IIa Trial
Per-Uno Malmstrom et al.
CLINICAL CANCER RESEARCH (2010)
CD40 Ligand-Induced Carcinoma Cell Death: A Balance between Activation of TNFR-Associated Factor (TRAF) 3-Dependent Death Signals and Suppression of TRAF6-Dependent Survival Signals
Taha Elmetwali et al.
JOURNAL OF IMMUNOLOGY (2010)
Phase 2 Trial of Single Agent Ipilimumab (Anti-CTLA-4) for Locally Advanced or Metastatic Pancreatic Adenocarcinoma
Richard E. Royal et al.
JOURNAL OF IMMUNOTHERAPY (2010)
Minimal RB-responsive E1A Promoter Modification to Attain Potency, Selectivity, and Transgene-arming Capacity in Oncolytic Adenoviruses
Juan J. Rojas et al.
MOLECULAR THERAPY (2010)
Multiple innate signaling pathways cooperate with CD40 to induce potent, CD70-dependent cellular immunity
Jennifer A. McWilliams et al.
VACCINE (2010)
Overcoming pre-existing adenovirus immunity by genetic engineering of adenovirus-based vectors
Sergey S. Seregin et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2009)
The Janus faces of CD40 in cancer
Angelica S. I. Loskog et al.
SEMINARS IN IMMUNOLOGY (2009)
Increased therapeutic efficacy of the prostate-specific oncolytic adenovirus Ad[I/PPT-E1A] by reduction of the insulator size and introduction of the full-length E3 region
A. Danielsson et al.
CANCER GENE THERAPY (2008)
Adenovirus vector-induced innate inflammatory mediators, MAPK signaling, as well as adaptive immune responses are dependent upon both TLR2 and TLR9 in vivo
Daniel M. Appledorn et al.
JOURNAL OF IMMUNOLOGY (2008)
Efficient adenovector CD40 ligand immunotherapy of canine malignant melanoma
Henrik von Euler et al.
JOURNAL OF IMMUNOTHERAPY (2008)
Phase 1, pharmacokinetic (PK) and pharmacodynamic (PD) study of oral alvespimycin (A; KOS-1022; 17-DMAG): Two different schedules in patients with advanced malignancies
K. T. Flaherty et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Sensing infection by adenovirus: Toll-like receptor-independent viral DNA recognition signals activation of the interferon regulatory factor 3 master regulator
Marcelo Nociari et al.
JOURNAL OF VIROLOGY (2007)
Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody
Robert H. Vonderheide et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Combined TLR/CD40 stimulation mediates potent cellular immunity by regulating dendritic cell expression of CD70 in vivo
Phillip J. Sanchez et al.
JOURNAL OF IMMUNOLOGY (2007)
A new group B adenovirus receptor is expressed at high levels on human stem and tumor cells
Sebastian Tuve et al.
JOURNAL OF VIROLOGY (2006)
Adenovirus-mediated CD40 ligand therapy induces tumor cell apoptosis and systemic immunity in the TRAMP-C2 mouse prostate cancer model
Helena Dzojic et al.
PROSTATE (2006)
Interactions of tumor necrosis factor (TNF) and TNF receptor family members in the mouse and human
Claudia Bossen et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2006)
Development of an adenoviral vector system with adenovirus serotype 35 tropism; efficient transient gene transfer into primary malignant hematopoietic cells
M Nilsson et al.
JOURNAL OF GENE MEDICINE (2004)
Adenovirus CD40 ligand gene therapy counteracts immune escape mechanisms in the tumor microenvironment
A Loskog et al.
JOURNAL OF IMMUNOLOGY (2004)
Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells
WW Overwijk et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2003)
In vitro activation of cancer patient-derived dendritic cells by tumor cells genetically modified to express CD154
A Loskog et al.
CANCER GENE THERAPY (2002)
Gene delivery from the E3 region of replicating human adenovirus: evaluation of the 6.7 K/gp19 K region
LK Hawkins et al.
GENE THERAPY (2001)
Phase I study of recombinant human CD40 ligand in cancer patients
RH Vonderheide et al.
JOURNAL OF CLINICAL ONCOLOGY (2001)
Autologous antileukemic immune response induced by chronic lymphocytic leukemia B cells expressing the CD40 ligand and interleukin 2 transgenes
S Takahashi et al.
HUMAN GENE THERAPY (2001)
The Rb/E2F pathway and cancer
JR Nevins
HUMAN MOLECULAR GENETICS (2001)
Share Paper
